Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 2/20 | 0.40 |
| ▸ | RARG | P13631 | 2/20 | 0.40 |
| ▸ | RARB | P10826 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.39 |
| ▸ | QDPR | P09417 | 2/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 4/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL677785 | 0.84 | ESR2 (0.42) | RARARARGRARBMAOBNR1H4 | |
| SCHEMBL612956 | 0.81 | MAOB (0.49) | RARARARGRARBMAOBNR1H4 | |
| SCHEMBL5962012 | 0.80 | ALOX12 (0.45) | RARARARGRARBNR1H4GAA | |
| SCHEMBL616710 | 0.77 | RARA (0.49) | RARARARGRARBMAOBNR1H4 | |
| SCHEMBL952469 | 0.76 | NR1H4 (0.54) | RARARARGRARBMAOBNR1H4 | |
| Idronoxil SCHEMBL29353213 | 0.76 | ESR2 (0.49) | RARARARGRARBMAOBNR1H4 | |
| Idronoxil SCHEMBL149612 | 0.76 | ESR2 (0.49) | RARARARGRARBMAOBNR1H4 | |
| SCHEMBL2755025 | 0.75 | KDM4E (0.42) | RARARARGRARBMAOBNR1H4 | |
| SCHEMBL3232102 | 0.73 | MIF (0.38) | RARARARGRARBHDAC6NR1H4 | |
| SCHEMBL13704314 | 0.72 | QDPR (0.43) | MAOBNR1H4QDPRGAAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312408-A1 | ISOFLAVAN AND ISOFLAVENE COMPOUNDS AND THEIR USE AS ANGIOGENESIS INHIBITORS | ADLERCREUTZ HERMAN | 2009-12-17 | — | — | US | claimed |
| EP-1991538-A1 | ISOFLAVAN AND ISOFLAVENE COMPOUNDS AND THEIR USE AS ANGIOGENESIS INHIBITORS | Adlercreutz, Herman (FI) | 2008-11-19 | — | — | EP | claimed |
| WO-2007096471-A1 | ISOFLAVAN AND ISOFLAVENE COMPOUNDS AND THEIR USE AS ANGIOGENESIS INHIBITORS | ADLERCREUTZ HERMAN (FI) | 2007-08-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312408-A1 | ISOFLAVAN AND ISOFLAVENE COMPOUNDS AND THEIR USE AS ANGIOGENESIS INHIBITORS | VEGFA, PGF, HIF1AN | RARA 3785/4885RARG 2958/4885RARB 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.